View ValuationGenmab 将来の成長Future 基準チェック /36Genmab利益と収益がそれぞれ年間17%と12.5%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に18.1% 16.9%なると予測されています。主要情報17.0%収益成長率16.85%EPS成長率Biotechs 収益成長20.5%収益成長率12.5%将来の株主資本利益率18.11%アナリストカバレッジGood最終更新日30 Apr 2026今後の成長に関する最新情報Genmab Provides Earnings Guidance for the Full Year 2026Feb 18Genmab Provides Earnings Guidance for the Full Year 2025Nov 08Genmab A/S Raises Earnings Guidance for the Year 2025Aug 07+ 1 more updateGenmab A/S Provides Revenue Guidance for 2025Feb 13+ 4 more updatesGenmab A/S Revises Earnings Guidance for the Year 2023Nov 08Genmab A/S Revises Earning Guidance for the Year 2023Jul 29すべての更新を表示Recent updatesGenmab A/S Presents Safety And Tolerability Data Of Rinatabart Sesutecan (Rina-S) In Combination With Bevacizumab In Advanced Ovarian CancerApr 14H Lundbeck A S Presents New Phase 1b Data for Lu Af28996 and Advances Pipeline in Movement DisordersMar 16Genmab A/S, Annual General Meeting, Mar 19, 2026Feb 19Genmab Provides Earnings Guidance for the Full Year 2026Feb 18Genmab A/S Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-Cell LymphomaJan 17Genmab A/S to Discontinue Further Clinical Development of Acasunlimab Following A Portfolio ReviewJan 01+ 1 more updateGenmab A/S (CPSE:GMAB) completed the acquisition of Merus N.V. (NasdaqGM:MRUS) in a tender offer transaction.Dec 12Genmab A/S Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular LymphomaNov 19Genmab A/S to Report First Half, 2026 Results on Aug 06, 2026Nov 14+ 3 more updatesGenmab Provides Earnings Guidance for the Full Year 2025Nov 08Genmab A/S Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®?) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial CancerOct 19Genmab Reportedly in Advanced Talks to Buy MerusSep 29+ 1 more updateGenmab A/S Announces Updated Results from Phase 2 Epcore®? Nhl-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)Sep 03Genmab A/S Raises Earnings Guidance for the Year 2025Aug 07+ 1 more updateGenmab Announces Changes to Its Executive CommitteeJul 02Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 TrialJun 03Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association (Eha) CongressMay 15Genmab A/S to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed Refractory Follicular LymphomaMay 02Genmab A/S Announces Japan Ministry of Health, Labour and Welfare Approves TIVDAK for the Treatment of Advanced or Recurrent Cervical CancerMar 28Genmab A/S Updates Data from Cohort B1 of the Phase 1/2 RAINFOL-01 Study of Rina-SMar 19Genmab A/S, Annual General Meeting, Mar 12, 2025Feb 14Genmab A/S Provides Revenue Guidance for 2025Feb 13+ 4 more updatesGenmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 TrialDec 08Third quarter 2024 earnings released: EPS: kr.19.94 (vs kr.32.60 in 3Q 2023) Nov 08Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug ConjugateSep 16Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaAug 20Genmab A/S Announces Executive ChangesAug 16Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023) Aug 11Genmab A/S Takes Full Control of Acasunlimab Development ProgramAug 06Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLYJun 27Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular LymphomaJun 05Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.May 22Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) CongressMay 15First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023) May 03Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical CancerApr 30Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.Apr 05Genmab A/S Announces Executive ChangesMar 14Executive VP & CFO recently sold €2.9m worth of stock Mar 03Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular LymphomaFeb 27Full year 2023 earnings released: EPS: kr.66.64 (vs kr.84.45 in FY 2022) Feb 16Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?Feb 03Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, IncJan 23Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License ApplicationJan 10Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular LymphomaDec 11Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular LymphomaNov 29Genmab A/S Revises Earnings Guidance for the Year 2023Nov 08New minor risk - Profit margin trend Nov 08Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022) Nov 08Genmab A/S, Annual General Meeting, Mar 13, 2024Oct 28Genmab A/S to Report Q1, 2024 Results on May 02, 2024Oct 27+ 3 more updatesGenmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global TrialOct 24New minor risk - Share price stability Oct 20Investor sentiment deteriorates as stock falls 17% Oct 18Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)Sep 26+ 1 more updateSeagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to ChemotherapySep 05Second quarter 2023 earnings released: EPS: kr.20.80 (vs kr.28.87 in 2Q 2022) Aug 04Second quarter 2023 earnings released: EPS: kr.20.80 (vs kr.28.87 in 2Q 2022) Aug 04Genmab A/S Revises Earning Guidance for the Year 2023Jul 29Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell LymphomaJul 23AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)Jun 28Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’Jun 23Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023Jun 09Co-Founder recently sold €7.8m worth of stock Jun 02U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell LymphomaMay 20Genmab A/S Provides Earnings Guidance for 2023May 11First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022) May 11Independent Chairman of the Board recently bought €107k worth of stock Apr 08Full year 2022 earnings released: EPS: kr.84.45 (vs kr.46.00 in FY 2021) Feb 24Insufficient new directors Feb 01Co-Founder recently sold €7.7m worth of stock Dec 16Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023Dec 10+ 3 more updatesThird quarter 2022 earnings released: EPS: kr.39.55 (vs kr.13.61 in 3Q 2021) Nov 10業績と収益の成長予測DB:GE9 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20286,3901,7602,6672,0531412/31/20275,1141,1121,6171,2881712/31/20264,3357418626891812/31/20253,7209631,1311,186N/A9/30/20253,8461,5831,2941,369N/A6/30/20253,6471,3711,0551,134N/A3/31/20253,2311,1401,1241,194N/A12/31/20243,1211,1331,0821,126N/A9/30/20242,9647029801,005N/A6/30/20242,743798939971N/A3/31/20242,576791775818N/A1/1/20242,3906311,0171,071N/A9/30/20232,389590806866N/A6/30/20232,378680826885N/A3/31/20232,216757902955N/A12/31/20222,088785518563N/A9/30/20221,580745459495N/A6/30/20221,438558277315N/A3/31/20221,342354201242N/A12/31/20211,288452302341N/A9/30/20211,232448148185N/A6/30/20211,168401894928N/A3/31/20211,703880856899N/A12/31/20201,6607811,0061,056N/A9/30/20201,7368891,1221,166N/A6/30/20201,559853357399N/A3/31/2020837349361383N/A12/31/2019806325182199N/A9/30/2019532223N/A198N/A6/30/2019487178N/A190N/A3/31/2019441202N/A180N/A12/31/2018464226N/A156N/A9/30/2018437222N/A165N/A6/30/2018397194N/A140N/A3/31/2018462213N/A215N/A12/31/2017381178N/A256N/A9/30/2017361184N/A200N/A6/30/2017356208N/A218N/A3/31/2017272174N/A156N/A12/31/2016257168N/A46N/A9/30/2016221111N/A99N/A6/30/2016205102N/A88N/A3/31/201618382N/A55N/A12/31/2015165111N/A45N/A9/30/201511666N/A10N/A6/30/201511569N/A3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: GE9の予測収益成長率 (年間17% ) は 貯蓄率 ( 1.7% ) を上回っています。収益対市場: GE9の収益 ( 17% ) はGerman市場 ( 16.1% ) よりも速いペースで成長すると予測されています。高成長収益: GE9の収益は増加すると予測されていますが、大幅には増加しません。収益対市場: GE9の収益 ( 12.5% ) German市場 ( 6.2% ) よりも速いペースで成長すると予測されています。高い収益成長: GE9の収益 ( 12.5% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: GE9の 自己資本利益率 は、3年後には低くなると予測されています ( 18.1 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/02 14:00終値2026/04/30 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Genmab A/S 18 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。41 アナリスト機関James GordonBarclaysXue ChenBarclaysEmily FieldBarclays38 その他のアナリストを表示
Genmab A/S Presents Safety And Tolerability Data Of Rinatabart Sesutecan (Rina-S) In Combination With Bevacizumab In Advanced Ovarian CancerApr 14
H Lundbeck A S Presents New Phase 1b Data for Lu Af28996 and Advances Pipeline in Movement DisordersMar 16
Genmab A/S Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed Refractory Diffuse Large B-Cell LymphomaJan 17
Genmab A/S to Discontinue Further Clinical Development of Acasunlimab Following A Portfolio ReviewJan 01+ 1 more update
Genmab A/S (CPSE:GMAB) completed the acquisition of Merus N.V. (NasdaqGM:MRUS) in a tender offer transaction.Dec 12
Genmab A/S Announces EPKINLY (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular LymphomaNov 19
Genmab A/S Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®?) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial CancerOct 19
Genmab A/S Announces Updated Results from Phase 2 Epcore®? Nhl-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)Sep 03
Genmab A/S Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 TrialJun 03
Genmab A/S to Present New and Updated Results from Its Robust Epcoritamab (Epkinly®) Development Program At the 2025 European Hematology Association (Eha) CongressMay 15
Genmab A/S to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed Refractory Follicular LymphomaMay 02
Genmab A/S Announces Japan Ministry of Health, Labour and Welfare Approves TIVDAK for the Treatment of Advanced or Recurrent Cervical CancerMar 28
Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug ConjugateSep 16
Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular LymphomaAug 20
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLYJun 27
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular LymphomaJun 05
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) CongressMay 15
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical CancerApr 30
Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.Apr 05
Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular LymphomaFeb 27
Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?Feb 03
Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, IncJan 23
Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License ApplicationJan 10
Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular LymphomaDec 11
Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular LymphomaNov 29
Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global TrialOct 24
Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)Sep 26+ 1 more update
Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to ChemotherapySep 05
Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell LymphomaJul 23
AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)Jun 28
Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’Jun 23
Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023Jun 09
U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell LymphomaMay 20